Comparative Pharmacology
Head-to-head clinical analysis: FLAC versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAC versus ORTIKOS.
FLAC vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Adults: 40 mg orally twice daily.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
2-4 hours; prolonged in renal impairment (up to 12 hours)
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid